The treatment outcome in patients with chronic myeloid leukaemia (CML) in blast crisis (BC) is unsatisfactory despite the use of allogeneic stem cell transplantation (ASCT). Moreover, in some patients ASCT is contraindicated, with limited treatment options. We report the case series of two patients with lymphoid BC CML in whom ASCT was not approachable. The first patient developed BC two months after diagnosis in association with dic(7;9)(p11.2;p11.2) and T315I mutation. Blast crisis with central nervous system leukemic involvement and K611N mutation of the SETD2 gene developed abruptly in the second patient five years after ceasing treatment with nilotinib in major molecular response (MMR) at the patient's request. Both underwent one course of chemotherapy in combination with rituximab and imatinib, followed by dasatinib and interferon α (INFα) treatment in the first and dasatinib alone in the second case. Deep molecular response (DMR; MR 4.0) was achieved within a short time in both cases. It is probable that DMR was caused by a specific immune response to CML cells, described in both agents. The challenging medical condition that prompted these case series, and the subsequent results, suggest a re-visit to the use of a combination of well-known drugs as an area for further investigation.

Department of Biology Faculty of Medicine and Dentistry Palacký University 779 00 Olomouc Czech Republic

Department of Haemato Oncology University Hospital Olomouc and Faculty of Medicine and Dentistry Palacký University 779 00 Olomouc Czech Republic

Department of Immunology University Hospital Olomouc and Faculty of Medicine and Dentistry Palacký University 779 00 Olomouc Czech Republic

Institute of Haematology and Blood Transfusion 120 00 Prague Czech Republic

Zobrazit více v PubMed

Khoury J.D., Solary E., Abla O., Akkari Y., Alaggio R., Apperley J.F., Bejar R., Berti E., Busque L., Chan J.K.C., et al. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719. doi: 10.1038/s41375-022-01613-1. PubMed DOI PMC

Hochhaus A., Baccarani M., Silver R.T., Schiffer C., Apperley J.F., Cervantes F., Clark R.E., Cortes J.E., Deininger M.W., Guilhot F., et al. European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia. Leukemia. 2020;34:966–984. doi: 10.1038/s41375-020-0776-2. PubMed DOI PMC

Sauβele S., Kalmanti L., Lauseker M. Management and Outcome of CML Blast Crisis: Results from the Randomized CML Study IV. Haematologica. 2014;99:275.

Lauseker M., Bachl K., Turkina A., Faber E., Prejzner W., Olsson-Strömberg U., Baccarani M., Lomaia E., Zackova D., Ossenkoppele G., et al. Prognosis of Patients with Chronic Myeloid Leukemia Presenting in Advanced Phase Is Defined Mainly by Blast Count, but Also by Age, Chromosomal Aberrations and Hemoglobin. Am. J. Hematol. 2019;94:1236–1243. doi: 10.1002/ajh.25628. PubMed DOI

Copland M. Treatment of Blast Phase Chronic Myeloid Leukaemia: A Rare and Challenging Entity. Br. J. Haematol. 2022;199:665–678. doi: 10.1111/bjh.18370. PubMed DOI PMC

Jain P., Kantarjian H.M., Ghorab A., Sasaki K., Jabbour E.J., Nogueras Gonzalez G., Kanagal-Shamanna R., Issa G.C., Garcia-Manero G., Kc D., et al. Prognostic Factors and Survival Outcomes in Patients with Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients. Cancer. 2017;123:4391–4402. doi: 10.1002/cncr.30864. PubMed DOI PMC

Hehlmann R., Saußele S., Voskanyan A., Silver R.T. Management of CML-Blast Crisis. Best Pract. Res. Clin. Haematol. 2016;29:295–307. doi: 10.1016/j.beha.2016.10.005. PubMed DOI

Saußele S., Silver R.T. Management of Chronic Myeloid Leukemia in Blast Crisis. Ann. Hematol. 2015;94:159–165. doi: 10.1007/s00277-015-2324-0. PubMed DOI

Strati P., Kantarjian H., Thomas D., O’Brien S., Konoplev S., Jorgensen J.L., Luthra R., Abruzzo L., Jabbour E., Quintas-Cardama A., et al. HCVAD plus Imatinib or Dasatinib in Lymphoid Blastic Phase Chronic Myeloid Leukemia. Cancer. 2014;120:373–380. doi: 10.1002/cncr.28433. PubMed DOI PMC

Jehn U., Heinemann V. Successful Treatment of Accelerated and Blastic Phase of Chronic Myeloid Leukemia with High-Dose Interferon-Alpha Combined with Hydroxyurea. Cancer Detect. Prev. 1998;22:258–264. doi: 10.1046/j.1525-1500.1998.0oa31.x. PubMed DOI

Kreutzman A., Rohon P., Faber E., Indrak K., Juvonen V., Kairisto V., Voglová J., Sinisalo M., Flochová E., Vakkila J., et al. Chronic Myeloid Leukemia Patients in Prolonged Remission Following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile. PLoS ONE. 2011;6:e23022. doi: 10.1371/journal.pone.0023022. PubMed DOI PMC

Talpaz M., Hehlmann R., Quintás-Cardama A., Mercer J., Cortes J. Re-Emergence of Interferon-α in the Treatment of Chronic Myeloid Leukemia. Leukemia. 2012;27:803–812. doi: 10.1038/leu.2012.313. PubMed DOI PMC

Jiang H., Xu L.-P., Liu D.-H., Liu K.-Y., Chen S.-S., Jiang B., Jiang Q., Chen H., Chen Y.-H., Han W., et al. Allogeneic Hematopoietic SCT in Combination with Tyrosine Kinase Inhibitor Treatment Compared with TKI Treatment Alone in CML Blast Crisis. Bone Marrow Transplant. 2014;49:1146–1154. doi: 10.1038/bmt.2014.146. PubMed DOI

Chalandon Y., Passweg J.R., Guglielmi C., Iacobelli S., Apperley J., Schaap N.P.M., Finke J., Robin M., Fedele R., Bron D., et al. Early Administration of Donor Lymphocyte Infusions upon Molecular Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia: A Study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014;99:1492–1498. doi: 10.3324/haematol.2013.100198. PubMed DOI PMC

Kantarjian H.M., Hughes T.P., Larson R.A., Kim D.-W., Issaragrisil S., le Coutre P., Etienne G., Boquimpani C., Pasquini R., Clark R.E., et al. Long-Term Outcomes with Frontline Nilotinib versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 10-Year Analysis. Leukemia. 2021;35:440–453. doi: 10.1038/s41375-020-01111-2. PubMed DOI PMC

Fabarius A., Leitner A., Hochhaus A., Müller M.C., Hanfstein B., Haferlach C., Göhring G., Schlegelberger B., Jotterand M., Reiter A., et al. Impact of Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML: Long-Term Observation of 1151 Patients from the Randomized CML Study IV. Blood. 2011;118:6760–6768. doi: 10.1182/blood-2011-08-373902. PubMed DOI

Johansson B., Fioretos T., Mitelman F. Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia. Acta Haematol. 2002;107:76–94. doi: 10.1159/000046636. PubMed DOI

Bacher U., Haferlach T., Hiddemann W., Schnittger S., Kern W., Schoch C. Additional Clonal Abnormalities in Philadelphia-Positive ALL and CML Demonstrate a Different Cytogenetic Pattern at Diagnosis and Follow Different Pathways at Progression. Cancer Genet. Cytogenet. 2005;157:53–61. doi: 10.1016/j.cancergencyto.2004.06.011. PubMed DOI

Crisan A.M., Coriu D., Arion C., Colita A., Jardan C. The Impact of Additional Cytogenetic Abnormalities at Diagnosis and during Therapy with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia. J. Med. Life. 2015;8:502–508. PubMed PMC

Saussele S., Richter J., Guilhot J., Gruber F.X., Hjorth-Hansen H., Almeida A., Janssen J.J.W.M., Mayer J., Koskenvesa P., Panayiotidis P., et al. Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (EURO-SKI): A Prespecified Interim Analysis of a Prospective, Multicentre, Non-Randomised, Trial. Lancet Oncol. 2018;19:747–757. doi: 10.1016/S1470-2045(18)30192-X. PubMed DOI

Rousselot P., Loiseau C., Delord M., Cayuela J.M., Spentchian M. Late Molecular Recurrences in Patients with Chronic Myeloid Leukemia Experiencing Treatment-Free Remission. Blood Adv. 2020;4:3034–3040. doi: 10.1182/bloodadvances.2020001772. PubMed DOI PMC

Skucha A., Ebner J., Grebien F. Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and Beyond. Int. J. Mol. Sci. 2019;20:1029. doi: 10.3390/ijms20051029. PubMed DOI PMC

Burchert A., Neubauer A. Interferon a and T-Cell Responses in Chronic Myeloid Leukemia. Leuk. Lymphoma. 2005;46:167–175. doi: 10.1080/10428190400012029. PubMed DOI

Mustjoki S., Ekblom M., Arstila T.P., Dybedal I., Epling-Burnette P.K., Guilhot F., Hjorth-Hansen H., Höglund M., Kovanen P., Laurinolli T., et al. Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. Leukemia. 2009;23:1398–1405. doi: 10.1038/leu.2009.46. PubMed DOI

Polivkova V., Rohon P., Klamova H., Cerna O., Divoka M., Curik N., Zach J., Novak M., Marinov I., Soverini S., et al. Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLoS ONE. 2016;11:e0155959. doi: 10.1371/journal.pone.0155959. PubMed DOI PMC

Hjorth-Hansen H., Stentoft J., Richter J., Koskenvesa P., Höglund M., Dreimane A., Porkka K., Gedde-Dahl T., Gjertsen B.T., Gruber F.X., et al. Safety and Efficacy of the Combination of Pegylated Interferon-A2b and Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. Leukemia. 2016;30:1853–1860. doi: 10.1038/leu.2016.121. PubMed DOI

Hughes A., Yong A.S.M. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Front. Immunol. 2017;8:469. PubMed PMC

Sacchi S., Kantarjian H., O’Brien S., Cohen P.R., Pierce S., Talpaz M. Immune-Mediated and Unusual Complications during Interferon Alfa Therapy in Chronic Myelogenous Leukemia. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1995;13:2401–2407. doi: 10.1200/JCO.1995.13.9.2401. PubMed DOI

Westerweel P.E., Boekhorst P.A.W.T., Levin M.-D., Cornelissen J.J. New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia. Front. Oncol. 2019;9:665. doi: 10.3389/fonc.2019.00665. PubMed DOI PMC